RESULTS: There were 20 males and 23 females with an average age of 50.6 years. Tumors localized on the left adrenal in 22 cases, on the right in 18, and bilaterally in 3. The average tumor diameter was 43.1 mm (13.0-120.0 mm). Eleven out of 43 patients (26%) developed HI. Nine patients had systolic blood pressure !200 mmHg and 2 had systolic blood pressure <80 mmHg during surgery. The mean age of patients was significantly higher among those with than among those without HI (60.3 vs 47.1 years, p[0.04). Mean 24-hour urinary adrenaline (161.2 vs 69.3 mg/day, p<0.01) and metanephrine (2.19 vs 1.24 mg/day, p[0.01) levels were significantly higher in patients with HI. Gender, tumor laterality, tumor size, plasma catecholamine levels, 24-hour urinary noradrenaline and dopamine levels, 24-hour urinary normetanephrine levels, and urinary vanillylmandelic acid levels did not accurately predict HI.
INTRODUCTION AND OBJECTIVES:
The safety and feasibility of partial adrenalectomy has been established, however long-term outcome data is limited. In this study we evaluate the recurrence and functional outcomes in a primarily hereditary cohort of patients undergoing partial adrenalectomy for pheochromocytoma.
METHODS: A retrospective review from a prospectively managed database of patients undergoing partial adrenalectomy from 1995-2018 at the National Cancer Institute was performed. Demographics, hereditary syndrome status, surgical indication, recurrence and steroid replacement status data were collected. Local recurrence was defined as imaging evidence of a recurrent or de novo lesion on the operative side. Steroid dependency was defined as requiring daily steroid replacement at time of last follow-up.
RESULTS: A total of 123 partial adrenalectomies, removing 161 tumors, were performed in 106 patients. The majority of patients had a known hereditary predisposition to develop bilateral, multifocal and recurrent pheochromocytoma, with VHL being the most common (83, 78.3 %). The majority of patients presented with symptoms suggestive of pheochromocytoma and/or elevated catecholamines. Median tumor size was found to be 2cm (IQR 1.5-2.8). Median follow-up in this cohort was 60 months . Local recurrence occurred in 17 patients (16%) and was managed with active surveillance or surgery. Median time to recurrence was 71 months . A single patient (1/106, 0.9%) developed metastatic spread of pheochromocytoma (bone and lung) approximately 14 years after his first of 2 partial adrenalectomies and remains alive under active surveillance. 10 patients (9.4%) were on daily steroid replacement at time of last follow-up. Five patients experienced a complication of !3 on the Clavien-dindo scale (4.1%). Three of these patients underwent concurrent surgery at the time of partial adrenalectomy (1 partial nephrectomy and 2 pancreas resections).
CONCLUSIONS 
MP69-08 MECA 79 POSITIVE HIGH ENDOTHELIAL VENULE (HEV) DENSITY MAY ASSOCIATE WITH TUMOR AGGRESSIVENESS OF PHEOCHROMOCYTOMA
Yasuhiro Hashimoto*, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Chikara Ohyama, Hirosaki, Japan INTRODUCTION AND OBJECTIVES: High endothelial venules (HEV) are present in lymph nodes and tertiary lymphoid organs. It has been reported that HEV density is associated with tumor aggressiveness of several carcinomas.MECA 79 antibody recognizes L-selectin ligand (6-sulfo sialyl Lewis X glycan) expressed in HEV. In the present study, we examined MECA79 (þ) HEV density in pheochromocytoma.
METHODS: Thirty-three patients with pheochromocytoma who underwent surgical treatment at the Hirosaki University hospital between January 2005 and December 2016 were enrolled. Tissue microarray for MECA 79 was performed, and HEV densities were calculated. HEV density <1.5/mm2 was defined as HEV (-); HEV density !1.5/mm2 was defined as HEV (þ). We also conducted immunohistochemistry of MIB-1 and calculated MIB-1 index.
RESULTS: Of 33 patients, 13 (39.3%) were male and 20 (60.6%) were female. The average age was 56.1 years (range, 12-78 years). The mean observation period was 74.4 months. Of 33 cases, 3 cases (9.1%) were malignant pheochromocytoma.
In our cohort, five cases (15.1%) were found to be HEV (þ). The mean HEV density was 1.84/mm 2 . (0-20.8) Interestingly, of HEV (þ) five cases, three cases were malignant pheochromocytomas. HEV density was significantly different between malignant pheochromocytoma (17.60 AE 2.44/mm 2 ) and pheochromocytoma (0.26 AE 0.18/ mm 2 , non-paired t-test: p <0.0001). However, MIB-1 index was not significantly different between malignant pheochromocytoma (2.27 AE 0.61%) and pheochromocytoma (1.69 AE 0.19%, non-paired t-test: p[0.359).
CONCLUSIONS: In the present study, MECA79 positive HEV density may be associated with tumor aggressiveness of pheochromocytoma. Despite the small sample size and preliminary nature of our study, our study provides valuable insights to guide future research.
